DNER drives glycolytic reprogramming in renal cell carcinoma by activating the JAK2/STAT3 signaling pathway
-
By
-
Anrui Li
-
Jing-wen Xu
-
Jian-hua Qin
-
Qi Yuan
-
Lichen Teng
-
May 22, 2026
-
Clinical Scorecard: DNER Modulates Glycolytic Metabolism in Renal Cell Carcinoma Through Activation of the JAK2/STAT3 Pathway
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | DNER activates the JAK2/STAT3 signaling pathway. |
| Target Population | |
| Care Setting | |
Key Highlights
Guideline-Based Recommendations
Diagnosis
Management
- R
- e
- m
- o
- v
- e
-
- u
- n
- s
- u
- p
- p
- o
- r
- t
- e
- d
-
- r
- e
- c
- o
- m
- m
- e
- n
- d
- a
- t
- i
- o
- n
-
- a
- b
- o
- u
- t
-
- t
- a
- r
- g
- e
- t
- i
- n
- g
-
- D
- N
- E
- R
- .
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Patients diagnosed with clear cell renal cell carcinoma.
DNER may serve as a therapeutic target, particularly in relation to metabolic reprogramming.
Clinical Best Practices
Related Resources & Content
